Bicycle therapies offer continued hope for advanced tumors
NCT ID NCT07681674
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This trial provides continued access to three experimental Bicycle therapies—zelenectide pevedotin, nuzefatide pevedotin, and BT7480—for people with advanced solid tumors who are already benefiting from them in another study. Participants continue their same treatment while researchers monitor long-term safety. The goal is to allow ongoing treatment for those who are tolerating it well and whose disease has not progressed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Zelenectide pevedotin, BT7480, Nuzefatide pevedotin
What this could lead to
If successful, this could provide a way for people with advanced solid tumors to keep receiving a promising experimental treatment that is helping them.
What could go wrong
This is a small, early-phase study focused on safety, not on proving the treatment works. The drugs are still experimental and may have unknown side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- SLC-3010 for Advanced Solid Tumors Trial NCT05525247
- DS1025a for Advanced Solid Tumors - Trial NCT07681882
- GFH276 Combo for RAS-Mutant Solid Tumors & PDAC NCT07678593
- SHR-4685 for Solid Tumors Phase 1 Trial NCT07676903
- Long-Term Safety Study of Gotistobart for Advanc NCT07659379
- Tulmimetostat Trial for Advanced Solid Tumors & NCT04104776